Amylospot
Amylospot is Bioquantis’ cutting-edge AI software transforming cardiac screening by enabling early and precise detection of transthyretin cardiac amyloidosis (aTTR). Designed for both specialists and general cardiologists, it enhances expert assessments while helping non-specialists identify early signs for timely referrals.
Powered by deep learning, Amylospot systematically analyzes echocardiographic video sequences with unmatched precision, streamlining decision-making and optimizing diagnostic workflows. Seamlessly integrated into clinical practice, it makes aTTR screening smarter, faster, and more reliable, ensuring patients receive the right care at the right time.
our team
Our experts
Yedid Elbez, Co-founder
Chief Technical Officier
Pr. Gabriel Steg, Co-founder
Chief Medical Officer
Pr. Gregory Ducrocq, Co-founder
Chief Clinical Officer
Catherine Dahlen
Chief Financial Officer
Pr. Vincent Algalarrondo
Head of the cardiac amyloidosis reference center, Bichat Hospital
Isabelle Wekstein
Lawyer at court, partner of WAN law firm
Oumaya Ibrahimi
Chief Regulatory Officer
Helene Abergel
Clinical Project Manager
Our support
Bioquantis is proud to collaborate with the Assistance Publique-Hôpitaux de Paris (AP-HP), the largest university hospital network in Europe. AP-HP encompasses 38 hospitals across the Paris metropolitan area, providing world-class medical care to approximately 8 million patients each year. This strategic partnership grants Bioquantis access to an extensive ecosystem of medical expertise, cutting-edge research, and vast clinical data, strengthening our ability to develop AI-powered solutions tailored to real-world clinical needs.
Through this collaboration, Bioquantis works hand in hand with leading cardiologists and researchers to refine our predictive models and diagnostic tools. By leveraging AP-HP’s renowned infrastructure and its commitment to innovation, we ensure that our technologies are designed to make a meaningful impact in clinical practice, improving patient outcomes and advancing the future of cardiology.
In 2024, Bioquantis received financial support from BPI France, a testament to the groundbreaking innovation we bring to the field of AI-driven cardiology. This recognition validates our mission to revolutionize cardiac screening tools through cutting-edge artificial intelligence and predictive analytics.
With the backing of BPI France, Bioquantis is further accelerating its research and development efforts, refining its solutions, and expanding its reach to ensure broader clinical adoption. This support reinforces our commitment to delivering transformative technologies that enhance patient care, optimize clinical decision-making, and shape the future of cardiovascular health.
In 2022, Bioquantis forged a strategic partnership with Pfizer to accelerate the development of an advanced AI-powered solution for the screening of transthyretin cardiac amyloidosis (aTTR). This collaboration unites Bioquantis’ expertise in artificial intelligence and predictive analytics with Pfizer’s excellence in the development of advanced treatments for cardiovascular diseases and global healthcare reach.
Through this alliance, Bioquantis gains access to crucial resources and industry-leading expertise, enabling us to refine and optimize our screening tools. Together, we are committed to transforming cardiac screening by equipping healthcare professionals with state-of-the-art solutions that enhance early detection, improve clinical workflows, and ultimately, lead to better patient outcomes. This partnership underscores our shared vision of leveraging technology to redefine the future of cardiology.
Ensuring the Highest Standards of Data Protection
At Bioquantis, we prioritize the security and confidentiality of patient data. Our infrastructure adheres to the highest security standards, ensuring that sensitive medical information remains protected at all times.
All data is stored on highly secure cloud servers certified with the SecNumCloud label, guaranteeing compliance with strict cybersecurity and data protection regulations. Additionally, we offer deployment options within hospital intranet networks, ensuring full data sovereignty and adherence to institutional security policies.
By implementing robust encryption protocols, access controls, and continuous monitoring, we safeguard patient data from unauthorized access, ensuring trust and reliability for healthcare professionals. Bioquantis remains committed to upholding the integrity of medical data while providing cutting-edge AI solutions for cardiology.
